Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Novavax (NVAX) Stock Price & Analysis

NVAX Stock Chart & Stats

MX$189.00-MX$3.07(-1.60%)
At close:
MXN 150MXN 2003 Aug19 Aug31 Aug15 Sep28 Sep12 Oct26 Oct
Day’s Range
MXN 189.00 - MXN 193.60
52-Week Range
MXN 115.00 - MXN 245.94
Previous Close
MXN 192.07
Volume
17
Average Volume (3M)
1,307
Market Cap
MXN 31.23B
Enterprise Value
MXN 1.13B
Total Cash (Recent Filing)
MXN 719.34M
Total Debt (Recent Filing)
MXN 295.60M
Price to Earnings (P/E)
―
Beta
0.84
Next Earnings
Nov 05, 2026 (Est.)
EPS Estimate
-6.5
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Matrix-M Platform Reach

A broad network of major pharmaceutical partners gives Matrix-M multiple paths into infectious disease and oncology applications. Rights covering more than 30 experimental areas can diversify future revenue opportunities and reduce reliance on Novavax’s current COVID-19 product.

Sanofi Milestone And Royalties

The Sanofi alliance is converting development progress into tangible revenue while preserving additional milestone and royalty opportunities. Phase 3 advancement also strengthens Novavax’s strategic role in combination vaccines and provides a durable partner-led commercialization channel.

Structural Cost Reduction

Large, targeted reductions in R&D and SG&A could materially lower the company’s break-even threshold and improve cash efficiency. Management’s plan to operate with less than half the current headcount supports a leaner model if execution preserves key platform capabilities.

Bears Say

Revenue And Earnings Volatility

The sharp shift from strong 2025 profitability to TTM losses shows that earnings depend heavily on uneven milestones, vaccine demand, and delivery timing. This volatility makes sustainable operating performance harder to establish and increases the risk that future growth will be inconsistent.

Negative Equity And Cash Burn

Persistent negative equity weakens solvency optics and limits financial flexibility, while multi-year cash burn suggests the business is not yet self-funding. Continued reliance on milestones, partnerships, or external financing could constrain investment choices and increase execution pressure.

Revenue Concentration And Partner Timing

Concentrating most annual revenue in one seasonal period leaves results exposed to vaccine timing and demand fluctuations. Uncertain partner-program schedules add another layer of variability, making it difficult to forecast when platform opportunities will translate into recurring commercial revenue.

Novavax News

NVAX FAQ

What was Novavax’s price range in the past 12 months?
Novavax lowest stock price was Mex$115.00 and its highest was Mex$245.94 in the past 12 months.
What is Novavax’s market cap?
Novavax’s market cap is Mex$31.23B.
When is Novavax’s upcoming earnings report date?
Novavax’s next earnings report is estimated for Nov 05, 2026 (not yet confirmed), which is in 4 days.
How were Novavax’s earnings last quarter?
Novavax released its earnings results on Aug 06, 2026. The company reported -Mex$6.012 earnings per share for the quarter, beating the consensus estimate of -Mex$7.139 by Mex$1.127.
Is Novavax overvalued?
According to Wall Street analysts Novavax’s price is currently Undervalued.
Does Novavax pay dividends?
Novavax does not currently pay dividends.
What is Novavax’s EPS estimate?
Novavax’s EPS estimate is -6.50.
How many shares outstanding does Novavax have?
Novavax has 164,945,720 shares outstanding.
What happened to Novavax’s price movement after its last earnings report?
Novavax reported an EPS of -Mex$6.012 in its last earnings report, beating expectations of -Mex$7.139. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novavax?
Hedge funds hold Novavax shares: hedge funds decreased their holdings by 74.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology